These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29106053)

  • 1. Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis.
    Weatherley B; McFadyen L; Tammara B
    Clin Transl Sci; 2018 Jan; 11(1):54-62. PubMed ID: 29106053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
    Stock T; Fleishaker D; Wang X; Mukherjee A; Mebus C
    Int J Rheum Dis; 2017 Aug; 20(8):960-970. PubMed ID: 28328159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.
    Buttgereit F; Strand V; Lee EB; Simon-Campos A; McCabe D; Genet A; Tammara B; Rojo R; Hey-Hadavi J
    RMD Open; 2019; 5(1):e000889. PubMed ID: 31168411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis.
    Conrado DJ; Krishnaswami S; Shoji S; Kolluri S; Hey-Hadavi J; McCabe D; Rojo R; Tammara BK
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):325-41. PubMed ID: 27178257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects
.
    Miyoshi S; Hey-Hadavi J; Nagaoka M; Tammara B
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):966-976. PubMed ID: 27781421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics.
    Shoji S; Suzuki A; Conrado DJ; Peterson MC; Hey-Hadavi J; McCabe D; Rojo R; Tammara BK
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):439-448. PubMed ID: 28556506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal and Hematologic Comparative Effects of Dissociated Agonist of the Glucocorticoid Receptor and Prednisone in Dogs With and Without Food Restriction.
    Radi ZA; Vogel WM; LaBranche T; Dybowski JA; Peraza MA; Portugal SS; Lettiere DJ
    Int J Toxicol; 2018; 37(3):223-233. PubMed ID: 29554821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor.
    Ripp SL; Mukherjee A; Eng H; Stock T; Fleishaker D; Checchio T; Tammara B
    Clin Pharmacol Drug Dev; 2018 Mar; 7(3):244-255. PubMed ID: 29112329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid receptor up-regulation in early rheumatoid arthritis treated with low dose prednisone or placebo.
    Huisman AM; Siewertsz van Everdingen AA; Wenting MJ; Lafeber F; van Reesema DR; Jacobs JW; Bijlsma JW
    Clin Exp Rheumatol; 2003; 21(2):217-20. PubMed ID: 12747278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
    Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
    Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
    Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of body condition on plasma prednisolone and prednisone concentrations in clinically healthy cats after single oral dose administration.
    Center SA; Randolph JF; Warner KL; Simpson KW; Rishniw M
    Res Vet Sci; 2013 Aug; 95(1):225-30. PubMed ID: 23473553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.
    Buttgereit F; Kent JD; Holt RJ; Grahn AY; Rice P; Alten R; Yazici Y
    Bull Hosp Jt Dis (2013); 2015 Jul; 73(3):168-77. PubMed ID: 26535595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
    Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
    Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
    J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
    Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study.
    Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Koike T; Nakamura H
    Osteoporos Int; 2016 Feb; 27(2):729-35. PubMed ID: 26294294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.